Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.

[1]  M. Gentzsch,et al.  Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation , 2016, Expert review of precision medicine and drug development.

[2]  David Y. Thomas,et al.  Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor) , 2016, British journal of pharmacology.

[3]  Thomas Ferkol,et al.  Precision Medicine: At What Price? , 2015, American journal of respiratory and critical care medicine.

[4]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[5]  V. Carbone,et al.  Drug–drug plasma protein binding interactions of ivacaftor , 2015, Journal of molecular recognition : JMR.

[6]  W. Lu,et al.  An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: application to a pharmacokinetic study. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  C. Wainwright.  Ivacaftor for patients with cystic fibrosis , 2014, Expert review of respiratory medicine.

[8]  G. Lukács,et al.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression , 2014, Science Translational Medicine.

[9]  N. Dokholyan,et al.  Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.

[10]  T. Hwang,et al.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle , 2013, Proceedings of the National Academy of Sciences.

[11]  C. Bear,et al.  Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner* ♦ , 2012, The Journal of Biological Chemistry.

[12]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[13]  P. Flume,et al.  The clinical approach to lung disease in patients with cystic fibrosis. , 2009, Seminars in respiratory and critical care medicine.

[14]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[15]  P. Renshaw,et al.  Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. , 2008, Archives of general psychiatry.

[16]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[17]  M. Buchwald,et al.  CFTR Expression and Organ Damage in Cystic Fibrosis , 1994, Annals of Internal Medicine.